Immuneering Lifts Phase 3 Pancreatic Cancer Trial To 570 Patients As Phase 2 Patients Outlive Projections
The drugmaker extends Phase 2 follow-up, targets cash into the fourth quarter of 2028 and says faster enrollment could pull in its mid-2028 readout.
Immuneering, a late-stage clinical oncology company, said Thursday it will expand its Phase 3 pancreatic cancer trial from 510 to about 570 patients because enrollment is running ahead of schedule, and that faster pace could pull forward its mid-2028 topline readout. It is also extending Phase 2 follow-up because patients are living longer than projected, in its third-quarter results.
Longer survival pushes data to 2027
Updated results from the atebimetinib plus modified gemcitabine/nab-paclitaxel arm of the Phase 2 first-line pancreatic cancer trial, covering 55 patients, are now expected in the first half of 2027. Follow-up was extended because patients on the combination are living longer than projected.
CEO Ben Zeskind said the 17.3 months median overall survival with excellent tolerability reported at ASCO is "unprecedented among agents targeting this pathway."
The Phase 3 trial, MAPKeeper 301, tests atebimetinib plus the chemotherapy combination against standard-of-care chemotherapy in first-line metastatic pancreatic cancer. Its topline readout is currently guided to mid-2028.
What the company develops
Immuneering is developing Deep Cyclic Inhibitors, oral drugs meant to disrupt cancer-driving signaling in cycles rather than continuously. Its lead candidate, atebimetinib, is a once-daily pill that targets MEK. The company has no approved products.
It also plans to dose the first patient in fourth quarter 2026 in a Phase 2 lung cancer trial combining atebimetinib with the anti-PD-1 drug cemiplimab, with preliminary data expected in late 2027.
Cash runway into late 2028
The company expects cash to fund operations into the fourth quarter of 2028, a guide that reflects the Phase 2 extension, expanded Phase 3 enrollment and commercial readiness activities.
Cash, cash equivalents and marketable securities were $166.1 million at September 30, down from $217.0 million at December 31, 2025.
The third-quarter net loss was $24.2 million, or $0.37 per share, against $15.0 million, or $0.38 per share, a year earlier. Research and development spending rose to $20.7 million from $10.9 million, which the company attributed to higher clinical costs on its lead program and more staff. General and administrative expense was $5.1 million, up from $4.5 million.
Updated Phase 2 data are due in the first half of 2027, and the Phase 3 topline remains guided to mid-2028.
Sources
- 8-K Filing — Immuneering Corp (IMRX) — SEC EDGAR
- Exhibit imrx-20261029xexx991.htm — Immuneering Corp 8-K exhibit — SEC EDGAR
- Immuneering Reports Third Quarter 2026 Financial Results — globenewswire.com
- Immuneering Presents Design and Methodology of Ongoing — globenewswire.com